- Home
- CUBI vs RCKT Comparison
CUBI vs RCKT Comparison
Compare CUBI & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CUBI | RCKT |
|---|---|---|
| Founded | 1994 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 340.9M |
| IPO Year | 2012 | N/A |
Fundamental Metrics
Financial Performance| Metric | CUBI | RCKT |
|---|---|---|
| Price | $72.54 | $3.41 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 14 |
| Target Price | ★ $84.14 | $29.12 |
| AVG Volume (30 Days) | 291.5K | ★ 2.3M |
| Earning Date | 01-22-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 4.96 | N/A |
| Revenue | ★ $651,983,000.00 | N/A |
| Revenue This Year | $16.77 | N/A |
| Revenue Next Year | $6.91 | N/A |
| P/E Ratio | $14.71 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $40.75 | $2.19 |
| 52 Week High | $73.94 | $13.50 |
Technical Indicators
Market Signals| Indicator | CUBI | RCKT |
|---|---|---|
| Relative Strength Index (RSI) | 65.95 | 52.07 |
| Support Level | $69.00 | $3.30 |
| Resistance Level | $73.94 | $3.65 |
| Average True Range (ATR) | 2.25 | 0.19 |
| MACD | 0.41 | 0.05 |
| Stochastic Oscillator | 87.07 | 66.22 |
Price Performance
Historical ComparisonAbout CUBI Customers Bancorp Inc
Customers Bancorp Inc is a bank holding company engaged in banking activities. It provides financial products and services to small and middle-market businesses, not-for-profits, and consumers. The company operates in Lending Activities, Commercial Lending, Consumer Lending, Private Banking, Deposit Products, Other Funding Sources and Financial Products and Services. The majority of revenue is derived from commercial lending.
About RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.